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Nutritional management of acute pancreatitis in a human 
immunodeficiency virus-infected patient
Introduction
A 37-year-old male patient was referred from a local clinic with a 
one-day history of severe abdominal pain and difficulty breathing. 
In casualty, the patient reported pain in the right and left upper 
quadrant and the epigastrium, radiating to the back, accompanied 
by a retrosternal burning sensation. No nausea or vomiting was 
reported, but he had been constipated for the past three days. He 
was also known to have human immunodeficiency virus (HIV), and 
had been on highly active antiretroviral treatment (HAART) since 
2008. On examination, the abdomen was distended, rigid and tender. 
On admission, the patient’s sodium and chloride levels were slightly 
decreased: 132 and 97 mmol/l, respectively. Albumin levels and 
haematocrit were towards the upper end of the normal range, 
indicating a mild degree of haemoconcentration. White cell count 
was elevated (12.13 x 109/l), while the serum amylase and liver 
enzymes were significantly elevated, i.e. amylase 1 643 units/l 
and alanine aminotransferase 110 U/l, aspartate aminotransferase 
96 U/l, alkaline phosphatase 143 U/l and gamma-glutamyl 
transferase 206 U/l. The patient was diagnosed with acute 
pancreatitis, and sent to theatre for an exploratory laparotomy on 
day one. The surgical procedure showed haemorrhagic necrotic 
pancreatitis, a severely inflamed omentum, peripancreatic free 
fluid, as well as signs of fatty necrosis on the retroperitoneum. A 
nasogastric tube for free drainage was inserted, and the patient 
was kept nil per os. His oral antiretroviral drugs were also stopped. 
Postoperatively, he was awake and responsive, but in a critical 
condition with a poor prognosis. He was transferred to an isolation room 
in the general surgical ward as no beds were available in the intensive 
care unit (ICU). An antispasmodic [Buscopan® intravenously (IV) 10 mg 
three times daily], a histamine-2-receptor antagonist (Cimetidine IV® 
200 mg twice daily), an analgesic (Omnopon® 20 mg three times 
daily), antibiotics (Rocephin® IV 1 g twice daily, Flagyl® IV 500 mg 
three times daily), and a motility agent (Maxalon® IV 10 mg three 
times daily) were prescribed. The patient’s condition remained critical 
over the next three days and the nasogastric drainage remained 
well above 500 ml/day. The clinical course was characterised by 
persistent abdominal distension, temperature spikes, blood culture-
confirmed bacterial infection and respiratory distress. Additional 
treatment included adapted antibiotics therapy (increased Rocephin® 
IV to 2 mg twice daily and Meronem® IV 1 g twice daily within eight 
hours), as well as oxygen therapy via a face mask.
The patient was referred to the dietitian on day three postoperatively 
once he had haemodynamically stabilised. A decision to start total 
parenteral nutrition (TPN) was made, and a central venous port (CVP) 
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Table I: Total parenteral nutrition recommendations and calculations pertaining to the patient
Energy or nutrient Nutritional recommendation Patient’s calculated 
requirements
Nutrition provided by 
commercially available 
TPN and IV glutamine from 
day five postoperatively, 
onwards
Comment
Energy (kcal/day) 25-30 kcal/kg/day 1 875-2 250 1 980 Meets requirements
Nitrogen (g/day) 0.2-0.24 g/kg/day 15-18 19.2 Meets requirements
Glutamine (g/day) 0.3-0.5 g/kg/day 22.5-37.5 26.92 Meets requirements
Carbohydrate (g/day) 3-5 g/kg/day 225-375 250 Meets requirements
Fat (g/day) 0.8-1.5 g/kg/day 68-112.5 100 Meets requirements
IV: intravenously, TPN: total parenteral nutrition
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requested. His albumin had decreased to 32 g/l after the laparotomy, 
but his urea and electrolytes profile was within the normal range. 
On day four, the patient was stable enough to be transported to 
the X-ray department for a confirmatory X-ray of the CVP location 
(mobile X-ray machines are only available in the ICU). TPN, as well as 
additional IV glutamine, were commenced on day four, and increased 
to the goal rate on day five. The patient’s nutritional requirements 
and calculations for TPN are detailed in Table I. 
Nasogastric drainage transiently decreased to 50 ml on day 
five, but increased dramatically to more than 1 000 ml/day on 
days six and seven while he was on continued TPN therapy. The 
patient complained of severe pain in the abdomen, and significant 
abdominal distension was noted. On day eight, the patient showed 
signs of wound dehiscence with herniation of a bowel loop which 
necessitated relaparotomy. During the latter procedure on day nine, 
a necrotic, gangrenous section of jejunum (approximately 30 cm) 
was removed and a primary end-to-end anastomosis performed. A 
nasogastric tube for free drainage was reinserted and initially less 
than 500 ml/day was drained on days nine and 10, but this increased 
to volumes of more than 1 000 ml/day on days 11-16. The patient’s 
blood glucose also increased to above 14 mmol/l on day 11 and he 
was started on an insulin sliding scale. The patient passed flatus 
on day 15, and the abdominal distension improved. The nasogastric 
drainage started decreasing by day 17 and all antibiotics were 
stopped. The nasogastric drainage decreased to less than 200 ml/
day on day 18. The nasogastric tube was removed and the patient 
started to mobilise. Semi-elemental feeds (30 ml every three hours 
taken orally) were ordered to test the tolerance of the enteral feeds 
on day 19, while the TPN was maintained at full rate. 
The patient refused oral intake on day 20 and his condition started 
deteriorating. A rectal tube and a nasogastric tube for drainage were 
re-inserted to relieve the pressure in the abdomen. These drained 
500 and 900 ml/day, respectively. A diagnosis of paralytic ileus 
was made, and the patient was started on an anticholinesterase 
(neostigmine 0.5 mg subcutaneously two times daily). The decision 
was taken to continue with TPN feedings only, and to stop all enteral 
feeds. This was continued for days 20-24, during which time the 
patient’s condition improved slightly. 
The patient developed severe diarrhoea on day 24 (six watery stools 
over the course of the day), which improved the following day (day 
25 postoperatively). It was decided to once again test feed using oral 
semi-elemental feeds (30 ml every three hours) in addition to the 
TPN. Despite being counselled, the patient also consumed yoghurt 
and custard brought to him by his family. His diarrhoea was very 
severe on day 26 (five watery stools over the course of the day) 
and abdominal distension was noted. The patient also presented 
with elevated blood glucose values and temperature spikes. Enteral 
feeds were stopped, and TPN was continued at the full rate. The 
diarrhoea and abdominal distension had improved by day 31. The 
patient removed his CVP line and refused its reinsertion, threatening 
to sign refusal of hospital treatment. After he was counselled on his 
condition and prognosis, he agreed to stay in the hospital. As the 
patient refused IV lines, TPN could not be continued and oral semi-
elemental feeds (30 ml every three hours) were started and were 
well tolerated. Oral polymeric sipfeeds (50 ml every three hours) 
were started on day 32 and were also well tolerated. The semi-
elemental feeds were consequently stopped. The patient decided to 
eat soft porridge that his family had brought on day 33. This was 
well tolerated  and a low-fat diet was ordered. In addition, the patient 
was restarted on HAART. The abdominal pain restarted on day 37, 
although no abdominal distension was noted. The patient was sent 
for a computed tomography (CT) scan of the abdomen, after which 
he was diagnosed with a pancreatic pseudocyst. Despite counselling 
by doctors in the ward, and against their advice, he signed refusal of 
hospital treatment on day 38 and discharged himself. 
Literature review
In its healthy state, the pancreas is responsible for the secretion of 
enzymes that assist in the digestion of starch, lipids and protein, and 
which are secreted in response to food intake.1 If these enzymes 
are activated prematurely, the pancreas becomes inflamed and 
necrotised as a consequence of autodigestion.2,3 Inflammatory 
disease of the pancreas can be classified as either acute or chronic 
in nature (acute or chronic pancreatitis).1 Patients experiencing acute 
pancreatitis usually complain of severe pain in the epigastrium, with 
occasional radiation to the back.4 The patient has to meet at least 
two of the following criteria for a diagnosis of acute pancreatitis 
to be made: typical pain in the upper abdomen, serum levels or 
amylase or lipase exceeding three times the upper limit of normal, 
and CT imaging analysis confirming the diagnosis.1,4 Discovering the 
aetiology of acute pancreatitis is critical for both the management 
and prevention of recurrent episodes.1 While alcoholic and biliary 
causes account for the majority of acute pancreatitis cases, a number 
of other causative factors may be involved.1 The acute inflammation 
in this patient may have specifically been the outcome of medicinal 
treatment (antiretroviral drugs like didanosine, acyclovir, lamivudine 
and stavudine) and/or infectious causes, including HIV.1,2 
Patients with HIV are at a far greater risk of developing acute 
pancreatitis, which may relate to the following three factors:2
•	 The direct toxic effects of antiretroviral drugs on the pancreatic 
cells.
•	 Immunodeficiency, which predisposes such individuals to 
pancreatic infections, and worsens their prognosis. Therefore, 
the progression of HIV increases the risk.
•	 Alcohol abuse in the patient population affected by HIV. 
Problems such as hypoalbuminaemia and anaemia are more 
common in HIV-infected patients, as are HIV-related symptoms 
like diarrhoea, fever and hepatomegaly. The hospital stay is often 
prolonged because of higher morbidity that relates to nosocomial 
infections, with a trend toward higher mortality. Complications like 
pancreatic pseudocysts, as well as respiratory and multi-organ 
failure may be seen. The discontinuation of the pancreatotoxins 
(in this case the HAART) is of extreme importance in drug-induced 
pancreatitis.2
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Laboratory investigations that confirm the diagnosis of acute 
pancreatitis include elevated serum amylase and lipase 
concentrations, although only one of these tests is required for a 
diagnosis. Although a number of tests are available to determine the 
severity of acute pancreatitis, only haematocrit and C-reactive protein 
(CRP) are routinely available. A haematocrit over 44% on admission, 
and a CRP > 150 g/l, 48 hours after the onset of symptoms are 
indicators of necrotising pancreatitis. Unfortunately, no CRP was 
available for the patient in this timeframe, but his haematocrit was 
significantly above this level, indicating haemoconcentration and a 
poor prognosis.1 
According to the 1992 International Symposium on Acute Pancreatitis 
that took place in Atlanta, acute pancreatitis can be classified as 
severe if the patient meets any one of the following criteria:1
•	 Organ failure, including at least one of the following: shock, 
pulmonary insufficiency, renal failure and gastrointestinal 
bleeding.
•	 Local complications, including necrosis, or an abscess or a 
pseudocyst.
•	 Systemic complications, including severe metabolic disturbances 
or disseminated intravascular coagulation.
•	 Three or more of the Ranson’s criteria, or eight or more of the 
Acute Physiology and Chronic Health Evaluation II criteria.
This patient had severe pancreatitis since he suffered from 
pulmonary insufficiency and necrosis of the jejunum. Later, the 
patient also developed a local complication in the form of a 
pseudocyst. A pseudocyst consists of fluid, tissue, pancreatic 
enzymes, blood and debris, and usually develops 4-6 weeks after 
the onset of pancreatitis. It may resolve spontaneously or may have 
to be drained.1 
The management of acute pancreatitis includes adequate fluid 
resuscitation, analgesia and prevention of organ failure. Pancreatic 
necrosis increases the risk of mortality, and surgery may be 
necessary, as was the case for this patient.1
Anthropometry
The patient reported weighing approximately 82 kg, three months 
prior to admission. His weight on referral was estimated to be 
approximately 75 kg. This indicates that he lost approximately 10% 
of his body weight in the preceding three months. His bed length was 
measured to be 1.85 m, leading to an assessment of a body mass 
index of 23.4 kg/m2, which was in accordance with his physical 
appearance. Therefore, the patient’s actual body weight was used 
in all calculations.
Nutritional management
Although the preferred route of nutritional support for patients with 
acute pancreatitis who require nutritional support is the enteral 
route, and not the parenteral route,5 this patient’s situation was 
complicated. 
When the enteral route is chosen, peptide-based (semi-elemental) 
feeds, preferably containing medium-chain triglycerides, are 
recommended as polymeric feeds stimulate the pancreas and 
may result in severe pain.5,6 The more recent consensus guidelines 
indicate that nasogastric feeds may be given,5 although jejunal feeds 
may be better tolerated, particularly in patients suffering from severe 
acute pancreatitis that includes inflammation of the retroperitoneum.6 
Since the patient was in urgent need of nutritional support at the 
goal rate because of the pre-morbid significant weight loss, as well 
as the surgical intervention (laparotomy) which showed evidence of 
peripancreatic fluid collection, inflammation and necrosis, as well 
as the persistently high nasogastric drainage, it was decided to 
commence parenteral nutrition (PN) via a CVP. The peripheral route 
was not considered for this patient since he was uncooperative 
and frequently pulled out his peripheral IV lines. Although PN can 
be associated with an increased risk of severe hyperglycaemia, 
catheter-related sepsis and metabolic disturbances, if nutritional 
requirements are not controlled, it attenuates stimulation of the 
pancreas and the associated secretions, and improves the patient’s 
nutritional status.7,8 
The international consensus guidelines recommend that patients 
with severe pancreatitis should receive early nutrition therapy.5 
The American Society for Parenteral and Enteral Nutrition (ASPEN) 
guidelines for adult critically ill patients state that the first 24-72 
hours following hospital admission, or the commencement of 
hypermetabolism, provide a window of opportunity for feeding.9 
The ESPEN guidelines on PN in pancreatitis also recommend that 
PN, if indicated, should be started as soon as possible, but only 
after adequate fluid resuscitation has taken place and once the 
patient is haemodynamically stable.8 This was only achieved 
between 24-48 hours after the initial laparotomy. The pain and 
inflammation associated with pancreatitis result in an increase 
in the basal metabolic rate, which is linked to a higher energy 
requirement.6,7 Hypermetabolism increases in relation to the severity 
and complications of a given clinical setting, and may be up to 40% 
higher than the predicted energy expenditure.7 In this case, acute 
pancreatitis with sepsis were further contributors to an elevation in 
energy requirements, as well as the patient’s chronic HIV infection 
and surgerical interventions.10 The energy recommendations for 
PN in acute pancreatitis should be calculated using 25 non-protein 
kcal/kg/day, and should not exceed 30 kcal/kg/day.5,8 This is in line 
with the guidelines for enteral nutrition for acute pancreatitis, as well 
as the enteral and parenteral nutrition guidelines for surgery.6,11 It 
was decided to use the lower recommended range (25 non-protein 
kcal/kg/day) to decrease the risk of hyperglycaemia and increases 
in serum triglyceride levels in this patient. Overfeeding, which is not 
generally recommended, should be avoided in this particular clinical 
setting.5,8 
In addition to hypermetabolism, patients experience an increased 
protein catabolism because of impaired protein synthesis and lower 
sensitivity to the protein-sparing effects of glucose.7,8 An adequate 
nitrogen supply is imperative, and the goal for patients with severe 
acute pancreatitis is 0.2-0.24 g nitrogen/kg/day, or an equivalent 
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of 1.2-1.5 g amino acids/kg/day.5,8 Glutamine supplementation is 
recommended at dosages of 0.3-0.6 g/kg alanyl-glutamine (Ala-Gln) 
dipeptide since it plays an important role in metabolic processes, 
resulting in a reduction of overall complications and a shorter 
hospital length of stay.5,8 The patient requirements were met by 
the glutamine contained in the PN solution, as well as additional 
intravenous glutamine in the form of the Ala-Gln dipeptide.
The carbohydrate metabolism in patients with acute pancreatitis 
is altered as these patients may have increased insulin resistance 
which is associated with an increased risk of hyperglycaemia.7,8 
Nevertheless, glucose is the preferred energy supply,5,8 and the 
maximal level of glucose oxidation is approximately 5-6 g/kg/day.8 
Preferably, the glucose should be administered at dosages between 
3 g/kg/day and 5 g/kg/day, contributing between 50% and 70% of 
the total energy.8 If necessary, exogenous insulin should be used to 
maintain blood glucose levels close to the normal range.8 Glucose 
was calculated to provide approximately 50% of the total energy to 
prevent overfeeding and excessive hyperglycaemia in this patient.
Although glucose is the preferred energy supply, patients with acute 
pancreatitis are also more dependent on the products of fatty acid 
oxidation as energy substrates.7,8 If the risk for triglyceridaemia is to 
be minimised, intravenous lipids should be given, considered to be 
safe for use in patients with pancreatitis.5,8 Infusion rates should not 
exceed 1.5 g/kg/day.8 The infusion rate for this patient was calculated 
as 1.3 g/kg/day. It is recommended that serum triglyceride levels are 
kept at < 4.6 mmol/l in patients on PN,5 and < 12 mmol/l in patients 
with acute pancreatitis.8 
The micronutrient recommendations for patients suffering from acute 
pancreatitis are no different to those for other critically ill patients. 
A daily dose of multivitamins and trace elements is recommended.8 
Although it has been suggested that tissue damage caused by free 
radicals contributes to the pathogenesis of acute pancreatitis, and 
thus, antioxidant supplementation may be beneficial,10 insufficient 
evidence is available to recommend the supplementation of 
supranormal micronutrient dosages.8 Therefore, the patient received 
vitamins and trace elements at the generally recommended 
supplementary levels as part of his daily TPN regimen. 
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